Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Platforms for Personalized Polytherapeutics Discovery in COVID-19

Journal of Molecular Biology(2021)10.1016/j.jmb.2021.166945Source: DataRank Database

Platforms for Personalized Polytherapeutics Discovery in COVID-19 is a research paper published in Journal of Molecular Biology (2021). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.34)OA: hybridTopics (57)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Chidinma Onweni,Victoria Zambito,DeLisa Fairweather ORCID,Kathryn McCormick,Hideki Ebihara ORCID

Live enrichment

PubMed:33753053 PMC:PMC7979270 OpenAlex:https://openalex.org/W3139175945

National Institutes of Health

Grant: R43NS108847

NIAID NIH HHS

Grant: R21 AI152318

NIAID NIH HHS

Grant: R21 AI154927

NIAID NIH HHS

Grant: R21 AI145356

National Institutes of Health

Grant: 1R43NS108847-01A1

Resubmission: Systems for Exploring Pathogenicity in Clinical Variants of a Presynaptic Protein Involved in Epilepsy

Small Business Innovation Research

FWCI

0.34

Citation Percentile

0.5%

Citation Trend

2022

2023

2024

hybridLicense: cc-by

journalhttps://www.sciencedirect.com/science/article/pii/S0022283621001467/pdf

HYBRIDhttps://www.sciencedirect.com/science/article/pii/S0022283621001467/pdf

publisherhttps://www.sciencedirect.com/science/article/pii/S0022283621001467/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0022283621001467?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0022283621001467?httpAccept=text/plain

Fields of Study

Genetics, Aging, and Longevity in Model OrganismsSARS-CoV-2 and COVID-19 ResearchMedicineBiology0301 basic medicine0303 health sciences03 medical and health sciencesAnimalsAnimals, Genetically ModifiedCOVID-19Caenorhabditis elegansDisease Models, AnimalDrug Evaluation, PreclinicalHumansInduced Pluripotent Stem CellsZebrafishCOVID-19 Drug Treatment

MeSH Terms

COVID-19COVID-19 Drug TreatmentAnimalsDisease Models, AnimalDrug Evaluation, PreclinicalHumansZebrafishCaenorhabditis elegansAnimals, Genetically ModifiedInduced Pluripotent Stem Cells

Keywords

Coronavirus disease 2019 (COVID-19)ZebrafishSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Computational biology2019-20 coronavirus outbreakDrug discoveryPandemicComputer scienceMedicineBiologyBioinformaticsVirologyGeneGeneticsPathologyInfectious disease (medical specialty)AntiviralSARS-CovACE2Combination therapyCovid-19Induced Pluripotent Stem CellsDrug Evaluation, PreclinicalCOVID-19 Drug TreatmentAnimals, Genetically ModifiedDisease Models, AnimalPerspectiveAnimalsHumansCaenorhabditis elegans

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being